Buserelin Acetate Injection

Buserelin Acetate Injection is an artificially synthesized medicinal substance that targets the human gonadal endocrine regulatory pathway. Its pharmacological mechanism is highly precise and distinct from conventional broad-spectrum drugs. Its clinical application scenarios are strictly defined, and its scope of application is highly focused. It only focuses on two major specialized medical fields, with no additional diagnostic and treatment adaptation directions, nor does it involve pharmacological expansion in other fields. This drug achieves precise intervention in the physiological activities of target organs by specifically regulating endocrine signaling. With stable and controllable pharmacological effects, it has become an indispensable specialized preparation in corresponding clinical specialties and plays a unique core medicinal value in adaptation scenarios. The following text will focus on the two established core clinical application directions of the drug, combined with actual diagnosis and treatment scenarios, to break down its specific action logic, practical value, and clinical core significance in detail, and fully present its exclusive medicinal application system.

Buserelin Acetate	Buserelin Acetate Injection

​

Buserelin Acetate COA

Certificate of Analysis
Compound name	Buserelin Acetate
Grade	Pharmaceutical grade
CAS No.	68630-75-1
Quantity	30g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202601090086
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

Special regulatory applications in the field of assisted reproductive technology

In the modern assisted reproductive clinical diagnosis and treatment system, in vitro fertilization and standardized ovulation induction procedures have extremely high requirements for the development rhythm of follicles and the stability of endocrine environment. Buserelin Acetate Injection is the core regulatory drug that adapts to this demand, mainly used for fine and comprehensive intervention in the maturation cycle and ovulation timing of follicles. The core purpose is to avoid sudden abnormal risks in clinical operations and establish a bottom line for the success rate of key diagnosis and treatment links. Its core practical role can be refined into the following specific dimensions:

• The preparation process and targeted ovulation induction clinical operation for specialized adaptation of test tube baby embryo cultivation, fully undertaking the core regulatory responsibility of controlled ovarian hyperstimulation, can conform to the standardized diagnosis and treatment norms of assisted reproduction, accurately control the overall rhythm of multi follicle synchronous development, and avoid the imbalance of follicle development affecting subsequent operations.
• By targeting the pituitary regulatory pathway, it effectively inhibits the premature secretion and abnormal release of luteinizing hormone, blocks the interference of disrupted endocrine signals on the normal maturation process of follicles, maintains a high degree of synchronization between the endocrine environment and the physiological development rhythm of follicles, and ensures that follicle development is in a controllable state.

• Thoroughly avoiding abnormal clinical conditions of premature follicular discharge from a pharmacological perspective, fundamentally eliminating operational failures caused by premature follicular shedding and inability to retrieve eggs, and building a solid foundation for the entire assisted reproductive process, reducing diagnostic and treatment errors and cycle waste.
• By relying on the continuous regulation of endocrine homeostasis throughout the process, we aim to comprehensively improve the success rate of egg retrieval operations and the quality assurance of eggs, clearing key obstacles for subsequent core processes such as in vitro embryo cultivation and transplantation, and facilitating the smooth progress of the entire assisted reproductive cycle.
• By ensuring full endocrine regulation throughout the process, the success rate of egg retrieval is comprehensively improved, clearing key obstacles for subsequent processes such as embryo cultivation.

• Specially adapted for in vitro fertilization cultivation and targeted ovulation induction medical operations, fully responsible for the core regulation of controlled ovarian hyperstimulation, accurately controlling the overall development rhythm of follicles, and meeting the standardized operational requirements of assisted reproduction.
• Targeted inhibition of premature secretion of luteinizing hormone in the pituitary gland, blocking the interference of abnormal endocrine signals on follicular maturation process, and maintaining synchronization between endocrine environment and follicular development.
• Effectively avoiding the abnormal situation of premature ovulation of follicles, fundamentally eliminating the problem of egg retrieval failure caused by premature discharge of follicles, and laying a solid foundation for assisted reproductive operations.

Information source:

National Pharmacopoeia Committee Clinical Medication Guidelines of the Pharmacopoeia of the People's Republic of China (Chemical and Biological Products Volume) Beijing: China Medical Science and Technology Press

Chen Xinqian, Jin Youyu, Tang Guang New Pharmacology (18th edition) Beijing: People's Health Publishing House

The core application of clinical endocrine therapy for advanced male prostate cancer

Advanced prostate cancer is a progressive disease with a high degree of malignancy and a high clinical incidence rate in the male genitourinary system. Most patients are in the stage of local invasion or distant metastasis when diagnosed, and have completely lost the best opportunity for diagnosis and treatment of radical surgery. This type of tumor is a typical hormone dependent malignant lesion. The whole process of cell proliferation, lesion invasion, and remote diffusion is highly dependent on the supply of testosterone, the core male hormone in the body. The concentration of testosterone directly determines the activity intensity and progress speed of the tumor. Simple symptomatic intervention can not curb the deterioration of the lesion. In clinical practice, the core treatment principle for this type of advanced patients is endocrine castration conservative treatment.

The core goal is to cut off the androgen supply chain that the tumor relies on for survival, and break the core conditions for its growth and proliferation. As a highly targeted specialized preparation in this treatment system, Buserelin Acetate Injection, with its specific and long-lasting gonadal axis regulation effect, avoids some of the shortcomings of traditional hormone drugs and has a milder and more controllable pharmacological effect. It has become an irreplaceable core drug in endocrine therapy for advanced prostate cancer. Its targeted therapeutic effect can be refined into the following core levels:

01

As a first-line core intervention drug, it has been officially included in the standardized endocrine therapy pathway and clinical diagnosis and treatment consensus for advanced prostate cancer in China. It is an exclusive adaptive drug for the conservative treatment of hormone dependent prostate cancer throughout the entire process, fully meeting the standardized diagnosis and treatment requirements of urological oncology. It not only meets the basic treatment needs of patients with different disease stages, but also takes into account the drug tolerance of elderly and weak patients who cannot tolerate high-intensity treatment, filling the core drug gap of long-term endocrine intervention for advanced prostate cancer. It is a core component that runs through the entire conservative treatment plan and is not an auxiliary palliative drug.

02

Accurately targeting the male hormone regulatory pathway in the human body, this product achieves long-term downregulation of testosterone concentration through continuous and stable pharmacological intervention, stabilizing it below the castration level and completely blocking the key hormone nutrient supply that prostate tumor cells rely on for growth and division. At the molecular level, it disrupts the proliferation basis of tumor cells, suppresses the overall activity and growth potential of lesions. Unlike short acting hormone inhibitors, this product does not have the problem of rapid rebound of hormone levels after short-term use, and its pharmacological stability far exceeds that of similar temporary dry preparations.

03

By relying on the long-term stable testosterone level control effect, the abnormal proliferation, local infiltration, and distant metastasis of tumor cells are continuously inhibited, effectively slowing down the overall progression of the disease, gradually reducing the lesion volume and controlling the spread range. At the same time, targeted relief of common physical discomfort symptoms such as frequent urination, difficulty urinating, and bone pain in late stage patients is achieved, greatly reducing the physiological pain and long-term diagnosis and treatment burden of patients. Ultimately, the core treatment goal of stabilizing the condition, improving the daily quality of life of patients, and prolonging the progression free survival cycle is achieved, creating more stable physical conditions for subsequent palliative support treatment and symptomatic adjustment.

Source of information:

Drug Evaluation Center of the National Medical Products Administration Standard drug instruction manual template for Buserelin Acetate Injection preparation

References

European Association of Urology (EAU). Prostate Cancer Diagnosis and Treatment Guidelines (2025 Edition)

Chinese Medical Association Urology Branch Chinese Prostate Cancer Diagnosis and Treatment Guidelines (2024 Edition)

FAQ

• What is buserelin Buserelin Acetate Injection used for?

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.

• What are the side effects of buserelin acetate?

Using too much Injection may make you feel weak, nervous, dizzy and sick. You may also have a headache, hot flushes, stomach pain, swelling of the legs and breast pain. You may also have pain, bleeding or hardening of the skin at the site of injection.

Hot Tags: buserelin acetate injection, China buserelin acetate injection manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, PT 141 Peptide Spray, glp1 shot, etelcalcetide structure